Bristol Myers partner Zai Lab plots KarXT filing in China after trial win

After the recent FDA approval for the promising schizophrenia drug Cobenfy (xanomeline and trospium chloride), Bristol Myers Squibb and its partners are moving fast to expand the global reach of the novel antipsychotic.